Phase 1 trial of TSR-033 planned to begin in mid-2017
WALTHAM, MA, USA I May 01, 2017 I TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND) Application for TSR-033 to the U.S. Food and Drug Administration. TSR-033 is a monoclonal antibody targeting LAG-3.
“The IND for TSR-033 is the third application from our immuno-oncology franchise to be submitted to the FDA within the past 17 months,” said Mary Lynne Hedley, Ph.D., President and COO of TESARO. “Our vision is that immuno-oncology candidates such as TSR-033, TSR-042, our anti-PD-1 antibody, and TSR-022, our anti-TIM-3 antibody, could become a foundation of cancer therapy regimens across a variety of tumor types. A Phase 1 clinical study of TSR-033 is planned to begin in mid-2017.”
About TSR-033
TSR-033 is a monoclonal antibody candidate targeting LAG-3 developed as part of collaboration between TESARO and AnaptysBio, Inc. This collaboration was initiated in March of 2014, and is focused on the development of monospecific antibody drugs targeting PD-1, TIM-3 (TSR-022), and LAG-3 (TSR-033), in addition to a bi-specific antibody drug candidate targeting PD-1/LAG-3.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com and follow us on Twitter and LinkedIn.
SOURCE: TESARO
Post Views: 47
Phase 1 trial of TSR-033 planned to begin in mid-2017
WALTHAM, MA, USA I May 01, 2017 I TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND) Application for TSR-033 to the U.S. Food and Drug Administration. TSR-033 is a monoclonal antibody targeting LAG-3.
“The IND for TSR-033 is the third application from our immuno-oncology franchise to be submitted to the FDA within the past 17 months,” said Mary Lynne Hedley, Ph.D., President and COO of TESARO. “Our vision is that immuno-oncology candidates such as TSR-033, TSR-042, our anti-PD-1 antibody, and TSR-022, our anti-TIM-3 antibody, could become a foundation of cancer therapy regimens across a variety of tumor types. A Phase 1 clinical study of TSR-033 is planned to begin in mid-2017.”
About TSR-033
TSR-033 is a monoclonal antibody candidate targeting LAG-3 developed as part of collaboration between TESARO and AnaptysBio, Inc. This collaboration was initiated in March of 2014, and is focused on the development of monospecific antibody drugs targeting PD-1, TIM-3 (TSR-022), and LAG-3 (TSR-033), in addition to a bi-specific antibody drug candidate targeting PD-1/LAG-3.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com and follow us on Twitter and LinkedIn.
SOURCE: TESARO
Post Views: 47
